

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/598,479-Conf. #5991
				Filing Date	August 31, 2006
				First Named Inventor	Lee T. Bacheler
				Art Unit	1631
				Examiner Name	J. Lin
Sheet	1	of	2	Attorney Docket Number	026038.0265PTUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		6,221,578	04/24/2001	de Bethune et al.	
		6,630,343	10/07/2003	Bartenschlager, R.	
		7,058,616	06/06/2006	Larder et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
		EP 0 945 443	09/29/1999	Andries et al.		
		EP 1 043 399	10/11/2000	Bartenschlager, R. (w/English-language Abstract)		
		WO 97/08310	03/06/1997	Rice et al.		
		WO 97/27480	07/31/1997	de Bethune et al.		
		WO 98/39031	09/11/1998	Rice et al.		
		WO 99/37821	07/29/1999	Isom et al.		
		WO 99/67417	12/29/1999	Erickson et al.		
		WO 00/27825	05/18/2000	De Corte et al.		
		WO 01/79540	10/25/2001	Larder et al.		
		WO 01/95230	12/13/2001	Larder et al.		
		WO 02/33402	04/25/2002	Hertogs et al.		
		WO 04/111907	12/23/2004	Van Marck et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALLISON et al., "Osteonecrosis in HIV Disease: Epidemiology, Etiologies, and Clinical Management," <i>AIDS</i> , 2003; 17:1-9.	
		DEGRUTTOLA et al., "The Relation Between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan," <i>Antiviral Therapy</i> , 2000; 5:41-48.	
		DELANEY et al., "Cross-Resistance Testing of Antihepadnaviral Compounds using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus," <i>Antimicrobial Agents and Chemotherapy</i> , 2001; 45(6):1705-1713.	
		GUOMING et al., "Resistance of Neisseria Gonorrhoeae Epidemic Strains to Antibiotics," <i>Sexually Transmitted Diseases</i> , 2000; 27(2):115-118.	
		HARRELL et al., "Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors," <i>Statist. Med.</i> , 1996; 15:361-387.	
Examiner Signature			Date Considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/598,479-Conf. #5991	
			Filing Date	August 31, 2006	
			First Named Inventor	Lee T. Bacheler	
			Art Unit	1631	
			Examiner Name	J. Lin	
Sheet	1	of	2	Attorney Docket Number	026038.0265PTUS

		HARRIGAN et al., "Impact of Moderate Decreases in Baseline NNRTI Susceptibility on Response to Antiretroviral Therapy," 4 th International Workshop on HIV Drug Resistance and Treatment Strategies, Sitges, Spain, 2000, Abstract 86.	
		HAUBRICH et al., "Clinical Utility of Resistance Testing: Retrospective and Prospective Data Supporting Use and Current Recommendations," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 2001; 26:S51-S59.	
		HAUBRICH et al., "Delavirdine Hypersusceptibility: Virological Response and Phenotypic Cut-Points Results from ACTG 359"; 11 th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2004, San Francisco, CA USA; Abstract 671.	
		HAYDEN et al., "Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families," <i>New Engl. J. Med.</i> , 1989; 321:1696-1702.	
		IWEN et al., "Revised Approach for Identification and Detection of Ampicillin and Vancomycin Resistance in <i>Enterococcus</i> Species by Using Micro Scan Panels," <i>Journal of Clinical Microbiology</i> , 1996; 34(7):1779-1783.	
		JAPOUR et al., "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrobial Agents and Chemotherapy</i> , 1993; 37(5):1095-1101.	
		KATZENSTEIN et al., "Phenotypic Susceptibility and Virological Outcome in Nucleoside-Experienced Patients Receiving Three or Four Antiretroviral Drugs," <i>AIDS</i> , 2003; 17:821-830.	
		KELLAM et al., "Recombinant Virus Assay: a Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrobial Agents and Chemotherapy</i> , 1994; 38(1):23-30.	
		KUSUMI et al., "Human Immunodeficiency Virus Type 1 Envelope Gene Structure and Diversity In Vivo and After Cocultivation in Vitro," <i>Journal of Virology</i> , 1992; 66(2):875-885.	
		LOZANO-CHIU et al., "Evaluation of a Colorimetric Method for Detecting Amphotericin B-Resistant <i>Candida</i> Isolates," <i>Diagnostic Microbiology and Infectious Disease</i> , 1998; 31(3):417-424.	
		PAUWELS et al., "Comprehensive HIV Drug Resistance Monitoring using Rapid, High-throughput Phenotypic and Genotypic Assays with Correlative Data Analysis," 2 nd Int'l Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 1998; Abstract 51.	
		TURAL et al., "Clinical Utility of HIV-1 Genotyping and Expert Advice: The Havana Trial," <i>AIDS</i> , 2002; 16(2):209-218.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--